Purdue-based cancer imaging firm lands $15M in funding
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
Health Care & Insurance
Articles
Republicans needed to make Obamacare work
Obama’s latest delay of Obamacare insurance rules could sabotage the law’s exchanges. The president must be counting on Republican critics, like Indiana Insurance Commissioner Stephen Robertson, to stop him.
Timing looks right for Biomet IPO
After private equity firms paid $11.4 billion for Biomet Inc. just months before the onset of a prolonged downturn, they are now trying to take the company public when U.S. consumer sentiment is on the upswing.
Health insurance brokers must change to survive
Employees, rather than employers, will soon choose their own health insurers—either through the Obamacare exchanges or through private exchanges. Does that mean health insurance brokers, the people who match up employers with insurers, will no longer be needed?
UIndy looking for developer for health sciences center
UIndy would be the main tenant in the 134,000-square-foot building, which is expected to cost as much as $30 million.
Two-year extension offered for canceled health plans
The extension was part of a major package of regulations that sets ground rules for 2015, the second year of government-subsidized health insurance markets under Obama's law — and the first year that larger employers will face a requirement to provide coverage.
Lilly diabetes drug rejected by FDA over manufacturing issue
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Insurers’ Obamacare losses may reach $5.5 billion, U.S. says
Health insurers such as Indianapolis-based WellPoint Inc. and Louisville-based Humana Inc. stand to receive $5.5 billion next year to cover losses from Obamacare in a program the law’s opponents label a bailout.
IU prof DiMarchi to join Inventors Hall of Fame
Richard DiMarchi is being honored for his work on Eli Lilly and Co.'s Humalog, which has been used by millions around the world to address the complications of diabetes.
House passes moratorium on nursing home construction
The bill passed 55-40 and now returns to the Indiana Senate, which has already passed the bill and can now approve changes made by the House or send the bill to a conference committee for further consideration.
Analysts: Endocyte likely to receive green light on first drug this month
The European Committee for Medicinal Products for Human Use is scheduled to meet March 17-20, and analysts expect the agency to vote during that meeting to approve vintafolide, Endocyte’s first drug, which treats ovarian cancer.
Indiana one of many states aiming to limit tanning
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
Kentucky’s largest health system makes major jobs cut
Hospital company KentuckyOne Health, which employs more than 14,000 people in Kentucky and southern Indiana, says it has laid off about 500 people.
Indy hospitals, doctors should start a price war
The choice for health care providers is binary: either limit patient choice through restricted networks or preserve patient choice by making price transparency real and usable. Hospitals and doctors would be better served by the latter.
2014 Health Care Heroes: Timmy Global Health
Community Achievement in Health Care Finalist
2014 Health Care Heroes: Patient Health Coaching, Franciscan Visiting Nurse Service
Community Achievement in Health Care Finalist
Biosimilars bill passes House, heads to governor
Pharmacists would be able to substitute an interchangeable biosimilar drug for a prescribed name-brand product under a bill passed by the Indiana House of Representatives on Tuesday.
Lilly diabetes drug matches competitors’ effectiveness
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
Indiana’s hospitals face Obamacare timing problem
The Obama administration’s delays of Obamacare’s employer mandate penalties mean it will be another year or two before hospitals see the additional revenue the law was supposed to bring them.